Clinical Trial Search Results

A scientist pointing to an image of a DNA chain.

Research Area

Medical Conditions

Enrollment Status

Conditions

NCT03213652

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROSI Genomic Alterations

You are being asked to participate in this study because you have a relapsed or refractory tumor without a proven treatment strategy for cure. The main goal of this study is to test any good and bad effects of the ensartinib on ...

NCT03213704

NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions

The overall goal of this study is to test any good and bad effects of the study drug LOXO-101 (larotrectinib) on your tumor.

NCT04320888

NCI-COG PEdiatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations

This is a Phase 2 study of a drug called LOXO-292. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer. LOXO-292 is experimental because it has not been proven t ...

NCT03213678

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors

This is a Phase 2 study of a drug called LY3023414. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer.

NCT03233204

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes

The main goal is to test any good and bad effects of the study drug olaparib on your tumor. A second goal of the study is to evaluate side effects that might be caused by olaparib and to learn more about the pharmacology (how y ...

NCT03526250

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

The main goal of this study is to test any good and bad effects of the palbociclib on your tumor. A second goal of the study is to evaluate side effects that might be caused by palbociclib.

NCT03213691

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate)in Patients with Tumors Harboring Activating MAPK Pathway Mutations

The main goal is to test any good and bad effects of the study drug selumetinib (AZD6244 hydrogen sulfate) on your tumor. A second goal of the study is to evaluate side effects that might be caused by selumetinib (AZD6244 hydro ...

NCT04284774

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations

This is a Phase 2 study of a study drug called tipifarnib. The main goal of the study is to find out what effect, good and/or bad effects the study drug tipifarnib may have on your tumor. A second goal of the study is to evalua ...

NCT03220035

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations

You are being asked to participate in this study because you have relapsed or refractory tumor without a proven treatment strategy for cure. The main goal is to test any good and bad effects of the study drug vemurafenib on you ...